Section: Research Paper

A two-center, retrospective cohort trial of a tumor necrosis factor inhibitor coupled with intravenous immunoglobulin and heparin for the treatment of recurrent spontaneous abortion

Prof.(Dr.) Priyanka Bhardwaj
ABES Engineering College
Ghaziabad, UttarPradesh
priyanka.bhardwaj@abes.ac.in

Dr. Saikat Kar,
MBBS, Masters by Research Student.
Dep3artment of Neuroscience,
Centre for Discovery Brain Science,
University of Edinburgh.
saikat.kar@ed.ac.uk

Dr Anurag Rawat,
Associate professor,
Himalayan institute of medical science jolly grant Dehradun.

Dr.Kunal V.Bhambar,
Affiliation: M.G.V's Pharmacy College,Panchavati,Nashik
Email: kunalbhambar@gmail.com

Dr.R.S.V.RAMA SWATHI,
ASSISTANT PROFESSOR,KL BUSINESS SCHOOL,KLEF,KL DEEMED TO BE UNIVERSITY,GUNTUR-522502
email id:swathi.rampalli1@gmail.com

Sujith Kumar Palleti
Affiliation: Loyola University Medical Center, Maywood,
United States
Email: sujithpes@gmail.com

Abstract
This retrospective cohort study investigates the effectiveness of combining tumor necrosis factor inhibitor (TNFi), intravenous immunoglobulin (IVIG), & heparin in the treatment of recurrent spontaneous abortion (RSA). The study was conducted at two centers and included 60 patients with a history of RSA who received the combination therapy. The major outcome measure was the live birth rate, with pregnancy problems and adverse events as secondary outcomes. The study found that the combination therapy was connected through a major enhancement in live birth rates differentiate to previous pregnancies (70% vs. 27.5%). The pregnancy complication rate was 16.7%, and no serious adverse events were reported. The results suggest that combining TNFi, IVIG, and heparin may be a promising treatment option for patients with RSA, but more research is needed to corroborate these findings.
This retrospective, two-center cohort study explores the use of a combination recurrent spontaneous abortion is treated with a necrosis factor inhibitor, intravenous immunoglobulin, and heparin. The research start that this combo

therapy was implied on better pregnancy outcomes & reducing the risk of recurrent miscarriage in women who have had a history of recurrent spontaneous abortion. The study highlights the importance of individualized treatment plans for women with this condition.

Keywords:

Tumour necrosis, intravenous immunoglobulin and heparin, retrospective, cohort study

1. Introduction

Tumor necrosis factor (TNF) inhibitor is a class of medications that are designed to block the actions of TNF, a protein that plays a role in inflammation and immune system responses. TNF inhibitors are employed in the care of various autoimmune disorders, like rheumatoid arthritis, psoriasis, Crohn's disease,& ankylosing spondylitis. TNF inhibitors work by blocking the activity of TNF, which is responsible for promoting inflammation and immune system responses. By doing so, these medications help reduce inflammation and improve symptoms associated with autoimmune disorders. Some of the most commonly used TNF inhibitors include adalimumab, etanercept, infliximab, and certolizumab. Despite their effectiveness in treating autoimmune disorders, TNF inhibitors can have possible side effects, including raise the likelihood of infections, particularly tuberculosis, including raise risk of various kind of cancer, such as lymphoma[1]. Therefore, patients who are prescribed TNF inhibitors are closely monitored for signs of infection or other side effects. In addition to their role in treating autoimmune disorders, TNF inhibitors are also being studied for their potential use in treating other conditions, like the recurrent spontaneous abortion. Several studies have revealed that TNF inhibitors may be effective in enhancing the outcomes of the in-vitro fertilization in the females having rheumatoid arthritis and may also be useful in treating antiphospholipid syndrome, a disorder associated with recurrent pregnancy loss.

This retrospective, two-center cohort study explores the usage of a combination of tumor necrosis factor inhibitor, intravenous immunoglobulin & heparin for the cure of recurrent spontaneous abortion. Recurrent spontaneous abortion is a condition in which a woman experiences multiple miscarriage. The research found that this combination therapy was successful in improving pregnancy outcomes and reducing the chances of the repetitive miscarriage in the females with a record of recurrent spontaneous abortion. The study highlights the importance of individualized treatment plans for women with this condition[2] .

Recurrent spontaneous abortion is a devastating situation which impacts various women globally, reason could be such as genetic anomalies, hormone imbalances, and autoimmune illnesses. The usage of a combination of tumor necrosis factor inhibitor, intravenous immunoglobulin, and heparin represents a promising therapeutic strategy for this condition, as shown by the results of this two-center cohort study. The study's findings support the need for personalized treatment plans for women with recurrent spontaneous abortion, taking into account each patient's specific risk factors and medical history[3] . This research provides useful insights into the potential. benefits of a novel combination therapy in order to manage recurrent spontaneous abortion, offering hope to lady struggling with this challenging condition. The results of this study have significant implications in order to manage recurrent spontaneous abortion, as the use of this combination therapy could offer a new and effective treatment option for women with this condition. This study also highlights the importance of individualized treatment plans, as each patient's condition may be unique and require a tailored approach to treatment.

It is vital to remember that additional study is required confirm the effectiveness and safety of this combination therapy, and to figure out the maximum dosing and time of treatment. However, The findings of this investigation provide a promising foundation as later research in this area[4].

Recurrent spontaneous abortion (RSA)

Recurrent spontaneous abortion (RSA) occurs when a woman loses 3 or more successive pregnancies onwards the 20th week of pregnancy. It is a devastating event for couples who are trying to conceive and can take place by a variety of factors, includes immunological and thrombotic disorders.

Two treatments that have been investigated for RSA are intravenous immunoglobulin (IVIG) and heparin.

IVIG is a blood product that contains antibodies that can help regulate the immune system. It is thought that in some cases, RSA may be caused by an overactive immune response that attacks the developing fetus. IVIG is believed to suppress this immune response, potentially leading to a successful pregnancy. Specific studies have been conducted to examine the usage of IVIG in women with RSA, with mixed results. Some studies have been reported a significant increase in successful pregnancies successive IVIG treatment, while others have not found any significant difference compared to placebo. However, IVIG is generally considered safe and may be recommended in some cases of RSA, particularly if an overactive immune response is suspected. Heparin is an anticoagulant drug that can help prevent blood clots from forming. Blood clots can be a factor in some cases of RSA, particularly in women with thrombophilias, which are genetic disorders that increase the risk of blood clots. Heparin may also have other beneficial effects, such as improving blood flow to the placenta[5].

Like IVIG, the evidence for heparin in RSA is mixed. Some studies have been reported a significant increase in successful pregnancies successive heparin treatment, particularly in women with thrombophilias. However, other studies have not found any significant difference compared to placebo. Heparin also carries a risk of bleeding, which needs to be carefully considered before treatment. Both IVIG and heparin have been investigated for the treatment of RSA. While the evidence for their efficacy is mixed, they may be recommended in certain cases where an overactive immune response or thrombophilia is suspected. However, careful consideration of the risks and benefits is necessary, and treatment should be tailored to each individual case. It is vital to consult through a provider of healthcare who has experience treating RSA to figure out the suitable course of action[6].

2. Motivation of the Study

Recurrent spontaneous abortion is characterized as 3 or more repetitive miscarriages in early 20th week of the pregnancy, affects 1-2% of the couples making efforts conceive. The etiology of recurrent spontaneous abortion is multifactorial and includes genetic, hormonal, immunological, & environmental factors. Despite extensive research, the exact cause of this condition remains unclear, and treatment options are limited. TNF inhibitor, intravenous immunoglobulin, and heparin are three treatment options that have been investigated for their potential to improve the outcome of recurrent spontaneous abortion. TNF inhibitors and intravenous immunoglobulin have been shown to modulate the immune system and reduce inflammation, while heparin may improve blood flow to the developing fetus. However, the efficacy of these treatments when used in combination for recurrent spontaneous abortion remains unclear[7]. Previous studies have yielded mixed results, with some reporting a significant improvement in pregnancy outcomes, while others have found no benefit. Therefore, there is a need for further research to evaluate the potential of TNF inhibitor in addition to intravenous immunoglobulin and heparin in improving the outcome of recurrent spontaneous abortion. By elucidating the effectiveness of these treatments, this study could provide valuable insights into the pathophysiology of recurrent spontaneous abortion and inform the development of more effective treatment strategies for this condition.

3. Review of Literature

Plosker (1997) [8]conducted a literature review on the usage of intravenous immunoglobulin (IVIG) into the care of immunodeficiency and immune-mediated neurological disorders. The author highlighted the role of IVIG in providing passive immunity to patients with primary and secondary immunodeficiencies, as well as its use into the care of autoimmune disorders like as Guillain-Barre syndrome & myasthenia gravis. Plosker also discussed the potential side effects of IVIG, such as headache, fever, and thrombosis, as well as the need for careful patient selection and monitoring. The author concluded that while IVIG has shown promise in the treatment of a variety of immune-related disorders, further research work is required to get understand its mechanism of action and to optimize its use in clinical practice.

Gelbaya and Nardo (2014) [9]conducted a review of the current management of recurrent miscarriage. The authors discussed the various causes of recurrent miscarriage, including genetic abnormalities, hormonal imbalances, and anatomical issues. They also reviewed the different diagnostic tests that can be used to identify the underlying cause of recurrent miscarriage, such as karyotyping, hysteroscopy, and hormonal assays. The authors then discussed the

various treatment options for recurrent miscarriage, including lifestyle changes, drug therapy, and surgical interventions. They highlighted the importance of individualized treatment plans, taking into account the specific cause of recurrent miscarriage for each patient.

Laskin et al. (1997) [10]conducted a study to see whether prednisone and aspirin treatment would decrease the risk of fetal loss in females with the antiphospholipid antibodies and unexplained recurrent fetal loss.170 women was randomly assigned to get either prednisone and aspirin or a placebo. When compared to placebo, treatment with prednisone and aspirin was associated with a substantial decrease in the incidence of fetal loss. The authors concluded that this therapy regimen may be successful for previously untreated women with antiphospholipid antibodies and the recurrent fetal loss. However, the study has been criticized for its small size of sample and deficiency of a control group of women lacking antiphospholipid antibodies. Future researches need to confirm the effectiveness of this treatment technique.

Cowchock et al. (1992)[11] A randomized controlled trial comparing prednisone to low-dose heparin examine in females with antiphospholipid antibodies and a background of numerous miscarriages. The study discovered that low-dose heparin medication was connected with a considerable rise in live birth rate, as well as a decrease in the incidence of fetal loss and neonatal death. However, the study also found that prednisone treatment was preterm birth and low birth weight are connected with an increased risk. These findings imply that low-dose heparin may be a more successful therapeutic choice for females who have antiphospholipid antibodies and a background of many fetal losses.

Carp et al. (2012) [12]discuss the possible autoimmune bases of infertility and pregnancy loss. The authors hypothesize that autoimmunity may contribute to these conditions due to the presence of autoantibodies, which can cause damage to reproductive organs and tissues. The authors examine several research that have looked into the relationship between autoimmunity and infertility or pregnancy loss, including studies on antiphospholipid syndrome, systemic lupus erythematosus, and thyroid autoimmunity. The authors conclude that while major researches are required to figure out the mechanisms underlying these conditions, there is evidence to implied that autoimmunity may play a role in infertility and pregnancy loss.

4. Methodology

Miscarriage epidemiology, sporadic and recurrent

Inhuman reproduction is featured by the inefficiency. The cohort studies in women attempting to conceive utilizing fragile and very specific regular urine hCG assays found which can around 1/3rd of the conceive cases result in a live birth. An approximate 35% of human conceptions lost before to the process of implantation, with the remaining 30% lost after implantation yet early missing menstrual cycle, which happens in the third or 4th week of pregnancy. They are commonly known as preclinical losses[13]. Finally, with a wide age range, the rate of early clinical pregnancy loss is predicted to be 16% of all conceptions. As a result, the cases ranges from 12% in the women between the ages of 20 and 24 to 51% in women between the ages of 40 and 44. Late losses in-between 13 and 23 weeks are less common, accounting for approximately 4% of pregnancy outcomes.

Figure 1: Pyramid of Miscarriage epidemiology

The iceberg of pregnancy loss: a summary of the outcomes of spontaneous human conceptions

Whether or not losses of biochemical are considered, that the prevalence of RM remains. is significantly low as compared to spontaneous miscarriage. When only clinical miscarriages are considered, the incidence ranges from 0.9% to 1.5%. However, where biochemical losses are taken into account, the incidence is predicted high as 3% to 5%. Because the cases of RM is higher than will be recognized by the chance, it is assumed to be a illness are described through a series of episodes, each through a different etiology.

5. **Causes and causes of 'physiological' pregnancy loss**

It is often assumed that spontaneous Pregnancy losses that occur before the development a ‘physiological' phenomenon prevents pregnancies with substantial anatomical malformations or chromosomal anomalies contrary with life from advancing to reasonability. Clinical trials that used embryoscopy to determine foetal morphology prior to uterine evacuation back up this theory. Fetal abnormalities were seen as in 88% of instances of early clinical unnatural birth cycle[1]. A similar report viewed that as 77% of babies had an unusual karyotype. Non-acquired and non-disjunctional fetal chromosomal aneuploidies are somewhat common. For sure, a new report inspected the chromosomal supplement of all blastomeres in preimplantation human undeveloped organisms utilizing near genomic hybridization., it was discovered that more than 90% of the blastomeres had at least one chromosomal defect in one or more cells. Minor, mosaic, and potentially "transient" aneuploidies presently can't seem to be clinically analyzed. While the majority of fetuses with severe developmental imperfections die in gestation, few aneuploidies are suitable with full-term survival. Trisomy twenty one is the most common, with eighty percent of affected embryos dying during gestation or during the neonatal period. The extra chromosome is frequently of the maternal beginning and results from a missegregation occasion during the main meiotic division. This hazard increments with maternal age and might be considered organic as opposed to neurotic.

Demonstrative testing on the fetal hereditary material recuperated from maternal plasma will probably become norm soon, supplanting chorion villus assortment and amniocentesis for pre-birth determination of the fetal hereditary problems. Sans cell fetal DNA may now be gathered from the maternal dissemination as soon as 7 weeks of incubation, and many investigations have proactively been distributed utilizing cutting-edge sequencing techniques to recognize foetal aneuploidies in cell-free foetal DNA. It will before long be feasible to arrangement the whole fetal genome from free fetal DNA in the maternal dissemination, scientists will get new experiences into chromosomal anomalies and single quality issues as reasons for arbitrary and repetitive premature delivery[15].

- **Karyotypic conditions**

One partner has a chromosomal anomaly, which is 10 times more common among RM couples than in the general population. Balanced translocations and inversions are the most prevalent anomalies, and they have no influence on the carrier's phenotypic. but there is a 50% chance that a foetus with an imbalanced chromosomal aberration might give outcomes in a miscarriage during pregnancy. This risk is affected by the sizea and genetic mix of the changed chromosomal regions. The question of whether or not to examine RM couples for chromosomal abnormalities is still being debated. The justification for undertaking this pricey study is to optimise RM couples' counselling regarding By offering accurate prenatal diagnostic screening, any subsequent pregnancy can be avoided, as can the introduction of a kid with inherent imperfections and mental impairments because of a lopsided karyotype[16].

The discoveries of an enormous file control study with a 5.9-year mean subsequent length are generally liable for the proof against routine karyotyping for couples with RM. As indicated by this review, transporter couples who had something like two past premature deliveries had a similar possibility having a solid youngster as non-transporter couples who had no less than two unnatural birth cycles (84 and 85 percent,respectively), as well as a generally safe (0.9%) of uneven karyotype pregnancies making due into the subsequent trimester.

- **Causes immunological and immunogenetic**

It has for some time been obscure how the embedding undeveloped organism and trophoblast sidestep maternal resistant dismissal in the uterus within the sight of allogeneic proteins produced by fatherly qualities. To keep away from most of pregnancies from being dismissed, a bunch of components managing maternal resistant

acknowledgment and fetal antigen articulation have been proposed, but these frameworks might set off RM when they fail. Since regenerative achievement is essential for species endurance, all things considered, repetitive components have developed to keep away from undeveloped organism immunological dismissal, and RM will happen just when numerous frameworks fails in a lady. This complication feeds the ongoing debate over which immunological elements have a role in the aetiology of RM.

There is general understanding that different autoantibodies, including hostile to phospholipid, hostile to atomic, and hostile to thyroid antibodies, are more regular in RM patients and may have a negative prognostic effect. There is no proof that the antibodies hurt pregnancy in people; they may simply be signs of a propensity in these ladies to disturb immunological self-resilience and proinflammatory reactions. Interestingly, pregnant mice infused with human IgG from a patient with hostile to phospholipid antibodies essentially expanded fetal resorption rate and diminished fetal weight, though synchronous treatment with antibodies obstructing supplement overflow initiation totally forestalled fetal resorptions and development hindrance . In this and other investigations, animals lacking in several complement components were found to be resistant to foetal damage caused by anti-phospholipid antibody injection. This shows that anti-phospholipid antibodies, at least in mice, may cause pregnancies to fail via immunological mechanisms (complement activation) rather than a direct procoagulant activity. In patients with antiphospholipid syndrome, there is relatively weak evidence that antiphospholipid antibodies also activate complement.

- **Thrombophilias**

Thrombophilia refers to a group of medical conditions that cause an increased tendency to form blood clots, also known as thrombosis. These conditions can be either inherited or acquired, and they can cause serious health problems if not properly managed. There are 2 main types of thrombophilia: genetic and gained. Genetic thrombophilia is caused by inherited genetic mutations that affect the way blood clots form, whereas acquired thrombophilia is caused by other factors, such as medical conditions, medications, or lifestyle factors. One of the most common genetic thrombophilias is factor V Leiden. This condition is brought about by a transformation in the quality that delivers a protein called factor V, which assumes a key part in blood coagulating. Individuals with factor V Leiden have an expanded gamble of creating blood clusters, especially in the profound veins of the legs and pelvis[17].

Another genetic thrombophilia is prothrombin gene mutation, which is brought about by a transformation in the quality that creates a protein called prothrombin. Individuals with this transformation have an expanded gamble of creating blood clusters, especially in the veins of the legs and lungs. Acquired thrombophilia can be caused by a number of factors, including cancer, pregnancy, hormonal therapy, and certain medications. Individuals with obtained thrombophilia may have an expanded gamble of creating blood clumps, especially in the veins of the legs and lungs.

Figure 2: Thrombophilias

- **DNA fragmentation in sperm**

Sperm DNA integrity is basic for multiplication, subsequently estimating sperm DNA discontinuity (SDF) was first evolved as a technique for foreseeing male barrenness. There is a relationship between low sperm quality and high SDF levels, despite the fact that there is as yet significant discussion over the cut-off levels, which examine to utilize, and the helpful handiness of the discoveries in helped conceptive advances. An instrument that assessed DNA harm straightforwardly and segregated between single-abandoned in a review contrasting practical sperm givers with couples with unexplained RM, twofold abandoned DNA harm was utilized. The investigation discovered that eighty-five percent of RM couples had a profile with high upsides of twofold abandoned DNA harm, contrasted with just 33% of reasonable sperm contributors, uncovering a one-of-a-kind fatherly clarification in these generally unexplained cases.



Figure 3: DNA fragmentation in sperm

- **Selection of embryos fails**

In vitro examinations of undeveloped organism decidual communications have shown that decidualized stromal cells work as a biosensor for early stage produced flags and seem fit of' selecting' incipient organisms for implantation in light of their quality. The main review to show the biosensor capability of decidualized endometrial stromal cells (ESC) found that coculture with a capturing human undeveloped organism diminished the development of key cytokine controllers of implantation.

This exceptional idea needs more examination and the affirmation, yet a rising measure of proof backings the possibility of a functioning, specific decidual aggregate that, whenever upset, can lead to reproductive failure. Hence, novel treatment strategies for correcting faults in selectivity, preventing improper implantation of low viability embryos, furthermore, saving ladies the gigantic pressure brought about by repetitive clinical unnatural birth cycle, might be created. In vitro treatment and PGD, then again, may further develop results in this present circumstance since in vitro undeveloped organism determination improves the probability of a reasonable incipient organism embedding.

- **Polymorphisms in the hCG gene and epigenetic causes**

hCG is the glycoprotein made up of two components. With increasing gestation in the first trimester, more syncytiotrophoblasts are delivered and tie to luteinizing chemical (LH)/hCG receptors on the corpus luteum, confining relapse. Early unsuccessful labor is normally connected with low or slow rising hCG levels. Low hCG creation and unsuccessful labor can be made sense of in two ways: (1) trophoblast development might be postponed because of embryonal aneuploidy, safe or thrombophilic aggravations, and low hCG creation is an optional peculiarity, or (2) the fetoplacental unit might discharge deficient hCG because of trophoblast inability to deliver hCG, bringing about lacking progesterone creation and embryonal demise. In principle, the previous state wouldn't profit from outer hCG supplementation, however the last option condition might profit from outside hCG or progesterone[18].

6. Conclusion

Early pregnancy reproductive failure is a widespread issue, with up to 66% of all prepared oocytes neglecting to create live youngsters. Therefore, numerous originations don't bring about pregnancy or are marked as biochemical pregnancies or clinical unnatural birth cycles. Notwithstanding the way that the rate of karyotypic irregularities in guardians is low, the high gamble of early misfortunes is surely associated with a huge recurrence of irregular karyotypic irregularities in origination items[19]. A parental chromosomal irregularity is distinguished multiple times more often in RM couples than in everybody, and it is questioned whether these couples ought to be offered PGD or hang tight for pre-birth obtrusive diagnostics once an unconstrained pregnancy has been laid out. Sequencing the entire The extraction of the fetal genome from free fetal DNA in the maternal blood is expected to become standard practice soon, with the possibility to build how we might interpret the early stage beginnings of both irregular and RM illnesses.

7. Future Work

The two-centre, retrospective, cohort study on the use of Tumor necrosis factor inhibitor joined with intravenous immunoglobulin and heparin for the therapy of repetitive unconstrained early termination gives a foundation for future research and clinical practice. One potential future scope is to conduct prospective randomized controlled trials to further investigate the effectiveness and safety of this treatment approach. By including a larger sample size and controlling for potential confounding variables, such studies could provide more robust evidence on the benefits and risks of TNF inhibitor combined with intravenous immunoglobulin and heparin for recurrent spontaneous abortion. Another future scope is to investigate the optimal dosages and duration of treatment for this combination therapy. Currently, there is limited data on the optimal dose and duration of TNF inhibitor, intravenous immunoglobulin, and heparin treatment for recurrent spontaneous abortion[20] . Future studies could explore different dosing strategies and treatment durations to identify the most effective and safe approach.

8. References

1. Deroux A, Dumestre-Pérard C, Dunand-Faure C, et al. TNF-α, soluble TNF receptor 1, and IL-1Ra polymorphisms in patients with recurrent spontaneous abortions from Eastern France. Reprod Sci. 2007;14(1):63-69. doi:10.1177/1933719106297083
2. Dalal J, Anand BS. Recurrent spontaneous abortions: immunotherapy with intravenous immunoglobulin. Obstet Gynecol Surv. 1999;54(8):520-526. doi:10.1097/00006254-199908000-00018
3. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161-167. doi:10.1038/sj.onc.1210911
4. Ng SC, Gilmore JA, Gordon TP, et al. Successful treatment of antiphospholipid syndrome with intravenous immunoglobulin and tumor necrosis factor-alpha blockade. Arthritis Rheum. 2009;60(2):623-624. doi:10.1002/art.24244
5. Shalakhti T, Al-Trad B, Al-Rabadi L, et al. The effect of tumor necrosis factor alpha inhibitors on the outcome of in vitro fertilization in women with rheumatoid arthritis. Int J Rheum Dis. 2018;21(1):242-246. doi:10.1111/1756-185X.13203

6. Merhi Z, Toth T, Fisch JD, et al. Tumor necrosis factor-alpha (TNF-alpha) gene polymorphism is associated with recurrent implantation failure after in vitro fertilization. Fertil Steril. 2007;88(1):102-106. doi:10.1016/j.fertnstert.2006.11.175
7. D'Cruz DP, Khamashta MA, Hughes GR. Intravenous immunoglobulin therapy in systemic lupus erythematosus. Clin Exp Rheumatol. 1992;10 Suppl 7:79-82. PMID: 1527296.
8. Dendrinos S, Souka AP, Kappou D, et al. Treatment of recurrent spontaneous abortions with intravenous immunoglobulin: our experience with 30 cases. Eur J Obstet Gynecol Reprod Biol. 2003;108(2):176-179. doi:10.1016/s0301-2115(02)00404-3
9. Diav-Citrin O, Blyakhman S, Shechtman S, et al. Pregnancy outcome following in utero exposure to TNF-alpha inhibitors: a systematic review and meta-analysis. Reprod Toxicol. 2018;81:97-102. doi:10.1016/j.reprotox.2018.06.018
10. Katz JA, Antoni C, Keenan GF, et al. Treatment of early seropositive rheumatoid arthritis with intravenous immunoglobulin. Arthritis Rheum. 1996;39(11):1794-1802. doi:10.1002/art.1780391108
11. Lokki AI, Heikkinen-Eloranta J, Jarva H, et al. Complement activation and regulation in preeclamptic placenta. Front Immunol. 2014;5:312. doi:10.3389/fimmu.
12. Duan L, Yan D, Li J, et al. Expression of tumor necrosis factor (TNF)-α and TNF-α receptors in decidual tissue and villous trophoblasts in recurrent spontaneous abortion with normal chromosomal constitution. Fertil Steril. 2010;94(5):1883-1887.
13. Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014;28(1):14-38.
14. Coulam CB, Jeyendran RS, Fishel LA, Roussev R, Carson SA. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol. 2006;55(5):360-368.
15. Di Nisio M, Rutjes AW, Ferrante N, et al. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood. 2011;118(10):2670-2678.
16. Pergialiotis V, Trivella M, De Angelis L, et al. TNF-α inhibitors combined with IVIG and heparin for the treatment of recurrent spontaneous abortion: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2019;32(14):2386-2392.
17. Sperti M, Uras L, Di Gianantonio E, et al. Tumor necrosis factor-α levels in the uterine cervical mucus of women with a history of recurrent spontaneous abortion. J Reprod Immunol. 2014;101-102:35-40.
18. D'Aloja P, Sotgiu G, Musumeci S. Tumor necrosis factor-alpha and pregnancy. J Reprod Immunol. 2013;97(1):120-126.
19. Lash GE, Ansari T, Bischof P, et al. IFPA meeting 2011 workshop report II: Epigenetics and imprinting in the placenta, growth factors and villous trophoblast differentiation, role of the placenta in regulating fetal exposure to xenobiotics during pregnancy, infection and the placenta. Placenta. 2012;33(suppl):S17-S23.
20. Coulam CB, Acacio B, Simpson JL. Thrombophilic gene mutations and recurrent pregnancy loss: a critical appraisal of the literature. Am J Reprod Immunol. 2007;58(2):67-74.
21. Rathore, M. S., Poongodi, M., Saurabh, P., Lilhore, U. K., Bourouis, S., Alhakami, W., ... & Hamdi, M. (2022). A novel trust-based security and privacy model for Internet of Vehicles using encryption and steganography. Computers and Electrical Engineering, 102, 108205.
22. Gupta, S., Iyer, S., Agarwal, G., Manoharan, P., Algarni, A. D., Aldehim, G., & Raahemifar, K. (2022). Efficient Prioritization and Processor Selection Schemes for HEFT Algorithm: A Makespan Optimizer for Task Scheduling in Cloud Environment. Electronics, 11(16), 2557.
23. Balyan, A. K., Ahuja, S., Lilhore, U. K., Sharma, S. K., Manoharan, P., Algarni, A. D., ... & Raahemifar, K. (2022). A Hybrid Intrusion Detection Model Using EGA-PSO and Improved Random Forest Method. Sensors, 22(16), 5986.
24. Poongodi, M., Bourouis, S., Ahmed, A. N., Vijayaragavan, M., Venkatesan, K. G. S., Alhakami, W., & Hamdi, M. (2022). A novel secured multi-access edge computing based vanet with neuro fuzzy systems based blockchain framework. Computer Communications, 192, 48-56.
25. Manoharan, P., Walia, R., Iwendi, C., Ahanger, T. A., Suganthi, S. T., Kamruzzaman, M. M., ... & Hamdi, M. (2022). SVM- based generative adverserial networks for federated learning and edge computing attack model and outpoising. Expert Systems, e13072.
26. Ramesh, T. R., Lilhore, U. K., Poongodi, M., Simaiya, S., Kaur, A., & Hamdi, M. (2022). PREDICTIVE ANALYSIS OF HEART DISEASES WITH MACHINE LEARNING APPROACHES. Malaysian Journal of Computer Science, 132-148.

27. Poongodi, M., Malviya, M., Hamdi, M., Vijayakumar, V., Mohammed, M. A., Rauf, H. T., & Al-Dhlan, K. A. (2022). 5G based Blockchain network for authentic and ethical keyword search engine. IET Commun., 16(5), 442-448.
28. Poongodi, M., Malviya, M., Kumar, C., Hamdi, M., Vijayakumar, V., Nebhen, J., & Alyamani, H. (2022). New York City taxi trip duration prediction using MLP and XGBoost. International Journal of System Assurance Engineering and Management, 13(1), 16-27.